To improve the utility of herpes simplex virus type 1 (HSV-1) vectors for gene therapy, the viral envelope needs to be manipulated to achieve cell-specific gene delivery. In this report, we have engineered an HSV-1 mutant virus, KgBpK À gC À , deleted for the glycoprotein C (gC) and the heparan sulfate-binding domain (pK) of gB, in order to express gC:preS1 and gC:preS1 active peptide (preS1ap) fusion molecules. PreS1, and a 27 amino acid active peptide inside preS1 (preS1ap), are supposed to be the molecules that the human hepatitis B virus (HBV) needs to bind specifically to hepatocytes. Biochemical analysis demonstrated that the gC:preS1ap fusion molecule was expressed and incorporated into the envelope of the recombinant HSV-1 virus KgBpK À gC:preS1ap. Moreover, KgBpK À gC:preS1ap recombinant virus gained a specific binding activity to an hepatoblastoma cell line (HepG2) with a consequent productive infection. In addition, anti-preS1-specific antibodies were shown to neutralize recombinant virus infectivity, and a synthetic preS1ap peptide was able to elute KgBpK À gC:pregC:preS1ap virus bound on HpeG2 cells. These data provide further evidence that HSV-1 can productively infect cells through a specific binding to a non-HSV-1 receptor. Furthermore, these data strongly support the hypothesis that the HBV preS1ap molecule is an HBV ligand to hepatocytes.
Introduction
Viral vectors represent the most efficient tools for gene transfer into cells both in vivo and in vitro. [1] [2] [3] [4] [5] The utility of these vectors is due to their ability to enter the host cells through recognition of cell surface receptors that leads to the delivery and the expression of the transgene of interest. Viral genomes have been extensively modified to eliminate pathogenic virus properties, while retaining the ability of the virus to establish latency or a latent-like state to provide a long-term expression of the transgene. The development of vectors capable of direct transfer of genes into specific tissue/organs in vivo will be essential to the successful treatment of human diseases by gene therapy. [6] [7] [8] [9] [10] [11] [12] [13] To achieve this goal, the virus host range needs to be modified by manipulation of the viral structures involved in the host cell recognition without compromising the ability of the virus to enter the cells and to express the transgene. 7, 9, 10, 12, 13 The liver is an important target for gene therapy. It is a central organ for important metabolic processes in which inborn errors of metabolism, often resulting in organspecific changes, can manifest as disease syndromes. [14] [15] [16] Owing to its particular situation with respect to blood circulation, the liver can serve as a secretory organ for the systemic delivery of therapeutic proteins. The liver parenchyma is readily accessible to large molecules such as DNA fragments or recombinant viruses present in the blood. 17 Many methods have been attempted for specific gene transfer to hepatocytes. By far, the most successful have been those using the retroviral vectors. 16, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] However, retroviral-mediated gene transfer is relatively inefficient. The inefficiency of retroviral vectors as vehicles for hepatocyte gene therapy results from the fact that these vectors require a replicating cell for stable expression. Normal adult hepatocytes have low replication rates, and as a result, retroviral-mediated gene transfer is less than 5% in freshly isolated hepatocytes. 18, 21, 27, 30 Recently, it has been suggested that herpes simplex virus type 1 (HSV-1)-derived vectors are potentially powerful tools for gene therapy of human liver disease and can be used to introduce and overexpress potential therapeutic genes in hepatocytes in vivo, such as those for LDL receptor, factor VII and IX, and alpha-1-antitrypsin. 20, 22, 26, 29 HSV-1 is an attractive vehicle for gene transfer because of its capacity to carry large, foreign DNA sequences and its ability to package vector DNA as concatamerized plasmids, referred to as amplicons. [31] [32] [33] [34] Moreover, HSV-1 cytotoxic features have been almost completely eliminated by the deletion of immediate-early (IE) genes, thus preventing the expression of both early and late functions, and achieving viral reactivation from latency without virus replication. [35] [36] [37] Long-term transgene expression has been shown in neurons, the natural host for latent viral infection, and in other cell types in which highly defective viral DNA can persist in a manner similar to latency. 37 In addition, attenuated replicationcompetent HSV vectors have been tested in clinical applications to destroy tumor (glioblastoma) cells specifically. However, the use of these attenuated viruses may be limited to specialized applications, such as with brain tumors, due to their ability to also infect nontumor cells. 6, [38] [39] [40] [41] Despite the considerable advantages of HSV vectors, the broad host range of HSV, which does not allow a direct targeting in vivo, can limit their use.
HSV-1 infection involves virus attachment to the cell surface membrane followed by virus penetration and entry of the nucleocapsid into the cytoplasm. The first step of virus attachment is mediated by the binding of glycoproteins B and C (gB and gC) to the cell surface glycosaminoglycans, mainly heparan sulfate (HS), and also dermatan sulfate and chondroitin sulfate. 42, 43 This binding, mostly associated with gC, represents about 85% of the total binding to Vero cells, the most commonly used cell type for HSV propagation. A recombinant virus deleted of gC and the HS binding domain of gB (a lysinerich domain termed as poly-K or pK), namely KgBpK À gC À , was shown to display an impaired binding to normal cells (85% decrease in binding) to an extent similar to the reduction in binding of wild-type virus to HS-deficient cells; however, these mutations do not prevent virus adsorption, due to the involvement of other receptors. 42 The initial binding of the virus to cell surface HS is followed by gD-mediated tight binding to secondary receptors. The first identified herpesvirus entry mediator, HVEM or HveA, is a member of the TNF-a/NGF receptor family and has a restricted cell type distribution. 44 A second gD receptor, HveC, is a member of the immunoglobulin superfamily and is widely expressed, providing a basis for the broad host range of HSV-1. 45 The sequential attachment steps lead to the fusion of the viral envelope with the cell surface membrane and viral entry into the cell. Virus penetration into cells requires gB, gD, and gH/gL, based on mutant virus studies, although the process is still not well understood.
Construction of targeted HSV-1 vectors is complicated by this cooperative and in some ways unknown process. Moreover, the virus envelope contains at least 11 glycoproteins (gB, gC, gD, gE, gG, gH, gI, gJ, gK, gL, and gM) among which only gB, gD, gH, and gL are essential for viral infection in cell culture, but the others can be required for some specific functions or infection of particular cell surfaces in vivo. [46] [47] [48] [49] [50] Depending on the need, the manipulation of both essential and accessory glycoproteins may prove useful for construction of HSV targeted vectors.
To target HSV-1 infection specifically to hepatocytes, at least two kinds of modification of the virus envelope will be required: (i) elimination of the natural tropism and (ii) expression of a new viral ligand capable of binding to cell surface receptors present on the hepatocyte surface in a manner that preserves the natural mechanism of entry through fusion of the viral envelope with the cell membrane and viral entry into the cell. The first step has been, in part, accomplished by deleting the HS binding capacity of HSV-1 with the construction of the KgBpK À gC À double mutant virus. 42 To address the second requirement, in this report, we have used a new viral ligand capable of binding specifically to hepatocytes, identified in the preS1 coded region of human hepatitis B virus (HBV) envelope protein, as the targeting molecule. In particular, a 27 amino-acid (aa) residue (preS1 active peptide (preS1ap)) has been shown to be recognized by both cell receptors and anti-HBV antibodies, and is thought to be responsible for HBV binding to hepatocytes. [51] [52] [53] [54] The HS binding domain of gC was genetically replaced by either preS1 or preS1ap molecules. Biochemical analysis demonstrated that both the gC:preS1 and the gC:preS1ap fusion molecules were expressed from recombinant viruses, but only the gC:preS1ap molecule was incorporated into virions. This KgBpK À gC:preS1ap recombinant virus showed a specific binding improvement to HepG2 cells, a human hepatoblastoma cell line, when compared to parental KgBpK À gC À strain or to the binding of both the viruses to Vero cells. Moreover, the KgBpK À gC:preS1ap recombinant virus was able to infect hepatocytes actively following binding to the HBV receptor. Furthermore, specific anti-preS1 antibodies showed a specific neutralizing activity against the KgBpK À gC:preS1ap recombinant virus, and a synthetic preS1ap peptide was able to elute the recombinant virus bound on HepG2 cell surface. This contribution is further evidence that HSV-1 tropism can be manipulated to recognize a non herpesvirus receptor, while maintaining the ability to infect actively the intended target cell. Moreover, these data strongly support the hypothesis that the HBV preS1ap molecule is the true HBV ligand to hepatocytes.
Results

Expression of gC:preS1ap and gC:preS1 fusion molecules in transfected cells
The first step of HSV-1 infection involves virus attachment to HS moieties present at the host cell surface through gB and gC, following which, virus envelope and cell membrane fusion result in the release of virus nucleocapsid into the cytoplasm. In order to redirect HSV-1 adsorption to a different receptor, we constructed two recombinant genes in which part of the extracytoplasmic domain of gC was replaced with HBV preS1 (Figure 1 ), which is supposed to be one of the mediators of HBV-specific binding to hepatocytes. Insertion of a gC:preS1 gene into an HS-binding-defective virus (KgBpK À gC À ) could have two goals: (i) to demonstrate that HSV-1 binding and infection can be redirected specifically towards hepatocytes; (ii) to demonstrate that the preS1 molecule, if able to confer to HSV-1 a new tropism similar to that shown by HBV, is a real mediator of HBV binding to hepatocytes.
In the first construct, gC:preS1ap (Figure 1b) , the sequence encoding for the preS1 active peptide (preS1ap; 27 aa) was used to replace in frame the coding sequence for aa 149-442 of HSV-1 wild-type gC. In this construct, the coding sequences for the signal peptide, the transmembrane domain, and the intracytoplasmic domain of gC were left intact. Removal of residues 149-442 deleted three predicted sites for N-linked oligosaccharides 55 placed at aa 181, 197, and 362 of gC, and is close to another predicted glycosilation site at aa 148. We constructed a second fusion protein, gC:preS1 (Figure 1c) , in which the entire preS1 coding sequence HSV-1 targeted infection to hepatocytes R Argnani et al (119 aa) was inserted in frame in place of aa 149-213 of gC. In this second construct, removal of residues 149-213 deleted two predicted sites for N-linked oligosaccharides 55 placed at aa 181 and 197 of gC, and is close to the predicted glycosilation site at aa 148. The constructs were subsequently sequenced to confirm both the presence of the exact preS1 or preS1ap sequences after PCR amplification and their cloning in frame within the gC coding region.
Wild-type gC and the two gC:preS1 fusion molecules were cloned into pcDNA3.1-expression vector in order to construct pcDNA-gC, pcDNA-gC:preS1ap, and pcDNAgC:preS1 vectors in which the gC genes are under the transcriptional control of human cytomegalovirus (HCMV) (IE) promoter. To examine the expression of gC:preS1ap and gC:preS1 recombinant molecules, these vectors were used to transfect Vero cells. The cell lysates, collected 48 h post-transfection, were analyzed by Western blotting using an anti-gC polyclonal antibody. GlycoproteinC was detected as precursor and mature forms (lane 1) when using an anti-gC antibody, as expected (Figure 2a) , and the gC:preS1ap chimeric protein was detected when using an anti-gC antibody (lane 3) showing a higher mobility on SDS-PAGE compared to wild-type gC, due to the deletion of 306 aa from gC and the addition of only 27 aa of the preS1ap molecule. The analysis of the gC:preS1 fusion protein (lane 4) showed a protein with a migration mobility similar to wild-type gC, probably due to the smaller deletion in gC (64 aa) and the addition of the entire 118 aa of the preS1 molecule. The slightly higher SDS-PAGE mobility of mature gC:preS1 compared to wild-type gC is due to the loss of at least two of the predicted glycosilation sites for gC. 56 As expected, in mocktransfected cells, it was impossible to detect specific proteins (lane 2).
Different polyclonal and monoclonal antibodies against either the preS1 or the preS1ap proteins failed 3, and 4 , respectively). The cell lysates were separated by SDS-PAGE, transferred to nitrocellulose membrane, incubated with an anti-gC polyclonal antibody (R47), and with an anti-rabbit HRP-conjugated monoclonal antibody. Detection was performed using an ECL kit as described by the manufacturer. Sizes are indicated in kilodaltons on the left. (b) Vero cells were mock transfected (panel 1) or transfected with the plasmids pcDNAgC, pcDNA-gC:preS1ap, and pcDNA-gC:preS1 (panels 2, 3, and 4, respectively). At 48 h post-transfection Vero cells monolayers were fixed, washed, and incubated for 2 h with an anti-preS1 specific monoclonal antibody (T-0606). The transfected cell monolayers were then washed and incubated for 45 min with a rhodamine-conjugated anti-mouse antibody.
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to recognize the fusion molecules, and control molecules when analyzed either by Western blotting or by immunoprecipitation analysis. However, one of these monoclonal antibodies (T-0606, reported in Material and methods) was able to reveal the gC:preS1 and gC:preS1ap fusion proteins when analyzed by immunofluorescence of transfected cell monolayers. As reported in Figure 2b , in Vero cells transfected either with the gC:preS1ap (panel 3) or with the gC:preS1 (panel 4) expression vectors, it was possible to detect the fusion proteins that were not present in mock-transfected cells (panel 1) or in cells transfected with a wild-type gC expression vector (panel 2). This result confirms the expression data obtained with the anti-gC antibody in Western blot. . The same probe did not hybridize with any fragment in the KgBpK À gC À parental strain (lane 2) in which the gC coding sequence had previously been deleted. 42 In Figure 3b , the [ These data demonstrated the isolation of KgBpK À gC:preS1ap and KgBpK À gC:preS1 recombinant viruses that, other than being deleted for extracytoplasmic domains of gC, contain the sequence encoding either the preS1ap or the preS1 molecule of HBV.
Construction of KgBpK
Evaluation of the incorporation of gC:preS1ap and gC:preS1 fusion molecules into the viral envelope
The presence of the preS1ap or preS1 coding sequences in the viral genome is not sufficient to redirect HSV-1 infection to hepatocytes. For this purpose, the fusion molecules need to be incorporated into the viral envelope to be exposed on the surface of the virus and to be able to recognize their receptor on the intended target cell. Hence, Vero cells infected with the mutant or control viruses were analyzed for the presence of both cellassociated and virus-associated gC:preS1ap and gC:preS1 fusion molecules by Western blot and immuno- To confirm these results, an anti-preS1-specific monoclonal antibody was used to detect the chimeric proteins by means of immunofluorescence on Vero cell monolayers infected with both the recombinant or the parental viruses. As shown in Figure 5 , the antibody failed to detect proteins either in the KOS (Figure 5a ) or in the KgBpK 
Attachment properties of KgBpK
À gC:preS1ap mutant virus
To demonstrate that the KgBpK À gC:preS1ap recombinant virus gained a new binding affinity towards hepatocytes, the specific target cells for HBV preS1 molecule, binding assays were performed. Since HBV selectively infects humans and chimpanzees, and hepatocytes from these species are not easily available or grown reproducibly in vitro, the human hepatoma cell line HepG2, having the biosynthetic capabilities of normal liver parenchymal cells, was selected for the binding experiments. 53 The presence of specific HBV receptors on HepG2 cells has been demonstrated previously. 53 At the same time, binding assays were also performed on Vero cells to evaluate if the gC:preS1ap fusion molecule could give to the recombinant KgBpK À gC:preS1ap virus an improved binding activity on Vero cells when compared to the parental KgBpK 
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of the viral envelope with the cell plasma membrane. It has been demonstrated that a reduction in virus binding to the cell surface corresponded to a decreased infectivity. Assays of the rate of virus entry into HepG2 cells, bearing the specific preS1 receptor, were performed to verify if a new binding ability, other than to HS, is sufficient to increase the efficiency of the entry of bound virus into cells. The rate of virus entry into host cells was determined as the rate at which a virus bound to the cell surface becomes resistant to acid treatment as a consequence of penetration of the virus into the host cell, compared with untreated virus controls. The results reported in Figure 7 show that the rate of entry of the KgBpK À gC:preS1ap mutant virus into HepG2 cells was higher when compared to the rate displayed by the parental KgBpK À gC À strain, although lower than the entry rate of the KOS HSV-1 wild-type strain. These data suggest that a stable attachment to the cells surface, different than attachment to HS, can contribute to HSV-1 infectivity by enhancing the penetration rate into the host cell.
Specificity of KgBpK
À gC:preS1ap virus binding to HepG2 cells
To evaluate the specificity of binding of gC:preS1ap molecule to the HBV cell receptor, two different assays were carried out. First, a neutralization assay was performed by using either: a rabbit polyclonal anti-HBs ]methionine-cysteine radiolabeled purified virions, at an MOI of 10 PFU/cell. The viruses were allowed to bind to the cell surface for 10-360 min, after which the unbound viruses were removed and the cell monolayers washed three times with cold TBS. Cell monolayers with bound virions were resuspended in 100 ml of lysis buffer (0.5 M Tris-HCl, 150 mM NaCl, 1% Triton X-100, 10 mg/ml aprotinin) and transferred to vials for liquid scintillation counting. Quantification of cell-associated labeled virions was determined with a beta counter. À gC À , and KgBpK À gC:preS1ap viruses was assessed on HepG2 cells. HepG2 cells were incubated with 200 PFU per well of each virus for an adsorption period of 2 h at 41C. The cells were then rinsed three times, overlaid with complete medium, and shifted to 371C to allow virus penetration. At selected time points, the cells were treated with 2 ml of glycine buffer or TBS for 1 min. The cell monolayers were then washed three times with complete medium, overlaid with medium containing methylcellulose, and incubated at 371C to allow viral plaques to form. After 48 h, cells were stained and plaques were counted. At each time point, the average number of plaques produced on glycine-treated monolayers was expressed as a percentage of the average number of plaques produced on TBS treated monolayers. Results are averages from triplicate wells. a For viral neutralization assays, viruses were incubated for 3 h at 371C with complement and with or without an anti-HBs antigen or an antipreS1-or an anti-gB1s-specific antibody. Vero cells monolayers in 12-well plates were infected for 1 h and 30 min at 371C with the neutralized viruses and then treated for 1 min with 1 ml of low-pH glycine to inactivate nonpenetrated virus. The cell monolayers were then washed three times with complete medium, overlaid with medium containing methylcellulose, and incubated at 371C to allow viral plaques to form. After 48 h, cells were stained and plaques were counted. The plaque number of viruses incubated with complement in the presence of antibody was expressed as the percentage of plaques formed following incubation with complement alone. Results are averages from triplicate wells. b Following a 2 h incubation at 41C of confluent monolayers of HepG2 cells in 12-well plates with 100 PFU of KOS, KgBpK À gC À , or KgBpK À gC:preS1ap viruses, the cells were washed three times with complete medium supplemented with 100 mg of synthetic preS1ap peptide per ml (or without preS1ap peptide in control wells), overlaid with medium containing methylcellulose, and incubated at 371C to allow viral plaques to form. After 48 h, cells were stained and plaques were counted. At each time point, the average number of plaques produced on peptide-washed monolayers was expressed as a percentage of the average number of plaques produced on complete mediumwashed monolayers. Results are averages from triplicate wells.
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antigen antibody, which is also able to recognize the preS1 region, a mouse monoclonal anti-preS1-specific antibody, or a rabbit polyclonal anti-gB1s-specific antibody produced in our laboratory. As shown in Table 1 , the binding of the KgBpK À gC:preS1ap recombinant virus was inhibited by about 35% using the polyclonal antibody against HBs antigen, and up to 60% with the more specific anti-preS1 monoclonal antibody. These data demonstrate that the preS1ap molecule is accessible to anti-preS1 antibodies and that this interaction blocks virus infectivity. As a positive control, the binding of the recombinant virus, and the binding of control viruses as well, was inhibited by the anti-gB1s antibody, demonstrating the specificity of inhibition displayed by the antipreS1 antibodies.
Second, an assay was performed to assess if a synthetic preS1ap peptide could elute KgBpK À gC:pregC:preS1ap recombinant virus bound onto HepG2 cell surface. As shown in Table 1 
Discussion
Gene therapy seems to be a rational approach to the treatment of a wide range of diseases, both single-gene disorders and those with a polygenic or multifactorial etiology. The ability to direct gene transfer to a particular class of target cells is important both to achieve a therapeutic effect and to limit potential adverse effects. The development of viral vectors that can be targeted to specific cell types might enable novel delivery strategies to be used and possibly reduce the infection of nontarget cells. [1] [2] [3] [4] [5] Viral vectors have a large potential in this regard since particular cell types exist that best support individual virus life cycles. The identification of receptors used by different virus groups and the studies defining receptor-ligand interactions provide good information to develop viruses with altered tropism. [6] [7] [8] [9] [10] [11] [12] [13] It has been demonstrated that viral vectors can be pseudotyped by inserting molecules from different viruses that allow a new host cell specificity. As an example, there have been several reports of the successful modification of retroviral env genes, 10, 13 either by substitution with env proteins from different retroviruses or by substituting the N-terminal domain of env with peptides known to bind to specific cell types. Recombinant adenoviruses (Ad) can also be modified to encode engineered hexon fiber or penton base to modify, respectively, virus attachment and entry. These modified Ad vectors demonstrated an increased transduction of target cell types lacking high levels of the normal Ad receptor, even if the binding to the natural Ad receptor still occurred. 9, 12 To date, various mutations or substitutions of HSV glycoproteins have been described to alter the virus host range. A novel cellular glycoprotein encoding the CD4 Tlymphocyte marker was introduced into the HSV envelope, but with an inefficient incorporation and without testing the virus infectivity. 57 Recombinant viruses have been isolated in which different HSV-1 glycoproteins were substituted with glycoproteins from other herpesviruses, but these recombinants were not studied for targeted infectivity or altered host range. Recently, a mutant HSV-1 virus deleted for HS binding domains (namely, gC and the pK region of gB) was reported to encode and incorporate a gC:EPO (erythropoietin) fusion protein. This mutant virus displayed an increased binding to EPO receptor bearingcells, but was not infectious probably due to its internalization by endocytosis and due to the absence of gD receptors on the target cell line. 11 In another report, a mutant virus, deleted for the HS binding domains of gB and gC, and deleted for the HveA binding site of gD was reported to encode and incorporate a gC:IL13 fusion protein, which gave the mutant virus the ability to bind to IL13Ra2 receptor-bearing cells. 58 Nevertheless, this mutant virus is still displaying the affinity for the HveC gD receptor.
Liver-directed gene-transfer procedures reported to date show numerous disadvantages: (i) naked DNA and nonviral gene-transfer vectors induce transient expression in only a limited number of cells; (ii) retrovirusmediated gene transfer is limited by the need to induce hepatocyte division; and (iii) first-generation Ad vectors are highly efficient but induce an immune response leading to the rapid rejection of transduced cells. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Promising new vector systems have emerged, among which HSV based vectors seem to display all the characteristics to transfer genes efficiently to hepatocytes. 20, 22, 26, 29 The results presented here (a) add new evidences to the hypothesis that HSV-1 binding to the cells can be re-directed; and (b) support the assumption that preS1ap is a molecule that HBV uses to bind to the hepatocytes.
In this report, experiments were designed to construct a mutant HSV-1 virus that could specifically bind and infect hepatocytes. In order to achieve this objective, we planned to: (i) construct chimeric envelope glycoproteins in which the extracytoplasmic domain of gC is genetically replaced from the entire preS1 molecule or from the peptide (preS1ap) supposed to be responsible for HBV binding to hepatocytes; (ii) demonstrate that the gC:preS1 and gC:preS1ap chimeric molecules could be expressed and incorporated into the viral envelope; and (iii) demonstrate that these chimeric molecules could selectively mediate virus attachment and infection to hepatocytes. We selected the preS1 molecule because different reports indicate the preS1 active peptide as the mediator of HBV-specific attachment to hepatocytes. [51] [52] [53] [54] Moreover, preS1 and preS1ap molecules are small peptides that should not perturb other HSV glycoproteins on the viral envelope. Finally, by demonstrating that preS1 confers to HSV-1 a specific binding activity to hepatocytes, we also demonstrate that this molecule is a real mediator for HBV attachment to liver cells. We selected gC to construct the preS1 fusion proteins as it is a well-characterized glycoprotein, not essential for the viral life cycle in tissue culture. Moreover, the functional gC domains (as HS binding and C3b component of HSV-1 targeted infection to hepatocytes R Argnani et al complements) are known and it is probably possible to delete and replace them with preS1. To insert the preS1 HBV molecule into the viral envelope, we engineered the gC coding sequence in order to delete different portions of the extra cytoplasmic domain. In the first construct, gC:preS1, the entire preS1 coding sequence (119 aa) was inserted in place of aa 149 to 213 of gC while in the second construct, gC:preS1ap, the preS1 active peptide (27 aa) was inserted in place of aa 149 to 442 of gC. As demonstrated by Western blot and immunofluorescence analysis, both gC and preS1 antigenic structures were preserved as the chimeric molecules were recognized by both specific anti-gC and anti-preS1 antibodies. Moreover, Western blot analysis using an anti-gC polyclonal antibody showed that the chimeric molecules were post-translationally modified, as it was possible to see both mature and immature forms of the proteins.
While both the chimeric proteins are expressed and post-translationally modified, both upon transfection or infection with the recombinant viruses KgBpK À gC:pre:S1 and KgBpK À gC:pre:S1ap, only the second, gC:pre:S1ap, is incorporated into the viral envelope. The incorporation of the gC:preS1ap molecule was confirmed by Western blot from purified viruses.
To demonstrate that a new binding activity had indeed been introduced into the background of a viral mutant deleted for HS binding activity, we needed to demonstrate that: first, the binding activity of KgBpK The improvement in viral binding to hepatocytes led to a significant improvement in viral penetration into the host cell. Furthermore, the virus was able to infect liver cells actively, thus confirming its utility for gene transfer to this tissue/organ.
The specificity of virus binding to hepatocytes and the involvement of preS1ap in binding were strongly supported by neutralization data showing the ability of specific anti-preS1 antibodies to block virus infectivity, and the ability of preS1ap synthetic peptide to elute recombinant KgBpK À gC:preS1ap virus bound to the cell surface of HepG2 cells.
Taken together, our results clearly showed that the recombinant KgBpK À gC:pre:S1ap virus achieved the objective to infect hepatocytes preferentially. However, in order to eliminate the residual binding activity of the recombinant virus to cells other than hepatocytes, experiments are in progress to further modify the KgBpK À gC:pre:S1ap virus envelope. For this purpose, we plan to substitute gD with a fusogenic glycoprotein, like the F glycoprotein of the SV5 paramyxovirus, that can act independent of the interaction with a receptor. 59 This strategy should eliminate the interaction with the widely distributed receptors for gD, leading to the construction of a liver-targeted HSV vector suitable for clinical application.
Material and methods
Cells and viruses
Vero cells (ATCC, Bethesda, MD, USA) were maintained at 371C in Dulbecco's modified minimal essential medium (DMEM) (Bio Witthaker Europe) supplemented with 10% fetal bovine serum and were used to propagate all the HSV-1 viral strains. HepG2 (human hepatoblastoma) cells (No. BS TCL 79; Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna, Brescia, Italy) were maintained at 371C in minimum essential medium supplemented with Earle' salts (MEMEarle) and 10% fetal bovine serum. All mutant and recombinant virus strains used were derivatives of HSV-1 strain KOS. The gC À -HCMV-lacZ KOS mutant (KCZ), and the HS-binding-defective viruses KgBpK À and KgBpK À gC À were described previously. 42 
Construction of plasmids
Plasmid pGEM-gC was created by inserting the HSV-1 gC coding sequence (UL44) from strain KOS into the cloning vector pGEM-5Zf( þ ) (Promega). An HpaI (93730)-HindIII (98823) HSV-1 fragment containing the gC coding sequence and modified to have XhoI recognition sequences at the extremities was inserted into the SalI recognition site of the pGEM-5Zf( þ ) plasmid. The sequence encoding the 27 aa peptide active in the binding of the preS1 region (preS1ap) of human hepatitis B virus (HBV) to hepatocytes was inserted in frame within the pGEM-gC plasmid to create pGEM-gC:preS1ap. The preS1ap coding sequence (81 bp) was PCR amplified with oligonucleotides encoding, respectively, EcoRI and XbaI 5 0 and 3 0 ends, digested with restriction endonucleases EcoRI and XbaI, and inserted into the corresponding sites of pGEM-gC (EcoRI-96751; XbaI-97669), thus by deleting the gC sequence encoding for aa 149-442. The sequence encoding the entire HBV preS1 region was inserted in frame within the pGEM-gC plasmid to create pGEMgC:preS1. The 119 aa preS1 coding sequence (357 bp) was PCR amplified with oligonucleotides encoding, respectively, EcoRI and EheI 5 0 and 3 0 ends, digested with restriction endonucleases EcoRI and EheI, and inserted into the corresponding sites of pGEM-gC (EcoRI-96751; EheI-96945), thus by deleting the gC sequence encoding for aa 149-213. The oligonucleotide used for PCR amplification, also inserted an NcoI recognition sequence at position 2 of the preS1 coding region. The gC, gC:preS1ap, and gC:preS1 coding sequences were excised with the restriction endonucleases NheI-BamHI and inserted into the corresponding sites of the cloning vector pcDNA3.1-(Invitrogen-Life Technologies) to create the pcDNA-gC, pcDNA-gC:preS1ap, and pcDNA-gC:preS1 plasmids in which the three gC genes are under control of the HCMV IE promoter. 
Construction and isolation of recombinant viruses
HSV-1 mutant viruses were constructed by standard methods for transfer procedures by using LipofectAmine (Invitrogen-Life Technologies) for cotransfection, and the viral recombinants were thrice plaque purified by limiting dilution prior to characterization. 32 P]-labeled NgoMIV fragment (415 bp) from pGEM-gC was used to confirm the partial deletion of the gC coding sequence in the recombinant viruses.
Purification of radiolabeled viruses
Virions used for binding assays were labeled with [ 35 S]methionine-cysteine as described elsewhere 42 and purified by centrifugation (VTi 65.1 Beckman rotor) through iodixanol gradients (OptiPrep, Nycomed Pharma) at 58 000 rpm for 4 h at 41C. The fractions containing the radiolabeled viruses were pooled, diluted in sterile TBS, and centrifuged at 20 000 rpm for 25 min at 41C in a JA20 rotor. The virus pellets were resuspended in TBS, and radioactivity was determined with a beta counter.
Western blot analysis of surface glycoproteins
Aliquots of purified virus were resuspended in 2X SDS gel loading buffer, separated on SDS-PAGE, and analyzed by Western blotting using an anti-gC polyclonal antibody (R47) or an anti-gB1s polyclonal antibody made in our laboratory.
Binding of radiolabeled viruses to cells
Monolayers of confluent Vero and HepG2 cells in 12-well plates were incubated at 41C with radiolabeled purified virions at an MOI of 10 PFU/cell. The viruses were allowed to bind to the cell surface for 10-360 min, after which the unbound viruses were removed and the cell monolayers washed three times with cold TBS. Cell monolayers with bound virions were resuspended in 100 ml of lysis buffer (0.5 M Tris-HCl, 150 mM NaCl, 1% Triton X-100, 10 mg/ml aprotinin) and transferred to vials for liquid scintillation counting. Quantification of cellassociated labeled virions was determined with a beta counter.
Virus penetration assay
The rate of virus penetration was assessed by determining the rate at which adsorbed virus became resistant to inactivation by a low-pH glycine buffer (0. Following virus adsorption the cells were rinsed three times, overlaid with complete medium, and shifted to 371C to allow virus penetration. At selected times after the temperature shift, wells were treated with 2 ml of glycine buffer for 1 min, while control wells were treated with 2 ml of TBS for 1 min. The monolayers were then washed three times with complete medium, overlaid with MEM-Earle containing 0.5% methyl cellulose, and incubated at 371C allowing plaques to form. Cells were then fixed and stained with crystal violet to visualize and count viral plaques.
Virus neutralization assay
KOS, KgBpK
À gC À , and KgBpK À gC:preS1ap viruses were incubated for 3 h at 371C with shaking, with 5 ml of rabbit complement (Invitrogen-Life Technologies) and with or without 30 ml of a polyclonal anti-HBs antigen (a kind gift from Dr F Bonelli, SORIN Biomedica) or 2 ml of antipreS1 T-0606 antibody. As a control, viruses were incubated with 5 ml of rabbit complement and with 30 ml an anti-gB1s polyclonal antibody made in our laboratory. The neutralized virus preparations were used to infect confluent Vero cell monolayers in 12-well plates for 1 h and 30 min at 371C with shaking. After the inocula were removed, the cell monolayers were treated HSV-1 targeted infection to hepatocytes R Argnani et al for 1 min with 1 ml of low-pH glycine buffer (0.1 M glycine, pH 3.0) to inactivate nonpenetrated virus. The cell monolayers were then washed three times with complete medium, overlaid with medium containing 0.5% methylcellulose, and virus plaques were allowed to form at 371C. Cells were then fixed and stained with crystal violet to visualize and count viral plaques.
Elution of bound virus with synthetic preS1ap peptide
Confluent monolayers of HepG2 cells in 12-well plates were infected with 100 PFU of KOS, KgBpK À gC À , or KgBpK À gC:preS1ap viruses. Following a 2 h incubation at 41C, the cells were washed three times with complete medium supplemented with 100 mg of synthetic preS1ap peptide per ml (or without synthetic preS1ap peptide in control wells). The cell monolayers were then overlaid with medium containing 0.5% methylcellulose at 371C to allow virus plaques to form. Cells were then fixed and stained with crystal violet for plaque quantification.
